Delay.......

[anonymous]

dumbest comment. And come one, biologics will not steal market share from a topical. Apples to oranges. Product approvals get delayed allllllll the time. Doubt execs were shocked. Think high level next time before commenting.

correct. unfortunately other topicals are coming up right behind us. starting to feel like this was a huge mistake coming here.

 

[anonymous]

correct. unfortunately other topicals are coming up right behind us. starting to feel like this was a huge mistake coming here.

Yes, those have WAY less baggage. This won’t be the easiest sell. Fortunately the new topicals are coming soon and other biologics look promising.

 

[anonymous]

Yes, those have WAY less baggage. This won’t be the easiest sell. Fortunately the new topicals are coming soon and other biologics look promising.

what topicals are you referring to? And biologics? What, Tralokinumab? That indication will be for moderate to severe and won’t launch until 2022. You should do more research before making ill-informed comments

 

[anonymous]

correct. unfortunately other topicals are coming up right behind us. starting to feel like this was a huge mistake coming here.

Yep, definitely was. You clearly didn’t do your research or read the posts on this company’s board

 

[anonymous]

what topicals are you referring to? And biologics? What, Tralokinumab? That indication will be for moderate to severe and won’t launch until 2022. You should do more research before making ill-informed comments

roflumilast, tapinarof, ucb’s bimekizumab, 3 oral jaks — should i go on, IDIOT? speak for yourself, MORON.

 

[anonymous]

what topicals are you referring to? And biologics? What, Tralokinumab? That indication will be for moderate to severe and won’t launch until 2022. You should do more research before making ill-informed comments

You act like 2022 is a long time from now…just going to wait it out here and bail.

 

[anonymous]

Yeah, morale is low in my team. Not sure how the rest of the division is feeling.

 

[anonymous]

roflumilast, tapinarof, ucb’s bimekizumab, 3 oral jaks — should i go on, IDIOT? speak for yourself, MORON.

bimi is for psoriasis, different disease state; tapinarof is going for initial psoriasis indication, AD is later and data is no where near as convincing as rux; oral JAKs are for moderate to severe and will carry a black box; roflumilast is a PDE-4 like eucrisa which again doesn’t have as strong of data and whose first indication will be for psoriasis. Yes there will be competitors but rux cream has a clear advantage of being first to market by a long shot for any other topical competing for the AD indication. Biologics will NOT be direct competitors to rux cream imo. My hunch is you don’t work here, but are just stirring shit up on this board, otherwise you wouldn’t be citing psoriasis products as competitors.

 

[anonymous]

roflumilast, tapinarof, ucb’s bimekizumab, 3 oral jaks — should i go on, IDIOT? speak for yourself, MORON.

bimekizumab is for psoriasis, different disease state and indication
Tapinarof initial indication is for psoriasis, AD is later and data no where near as convincing as rux cream
Roflumilast is a pde-4 like eucrisa and first indication will be psoriasis and again, data is not as strong for AD compared to rux cream
Oral JAKs are for moderate to severe AD and will carry a black box so will have bigger hurdles to overcome imo
Rux Cream is the only topical JAK that will hot market in next 1-2 years so great opportunity for 1st move like dupilumab.
Biologics for AD won’t be direct competitors for rux cream
Based on you citing agents that aren’t even indicated for AD, my gut tells me you don’t work here but are just looking to stir shit up on this thread.
The biggest hurdle for rux cream will be access, but without any other topical JAKs on market for at least 1-2 years, this will be Incyte’s blunder if it’s not a blockbuster. so please, continue to go on.

 

[anonymous]

bimekizumab is for psoriasis, different disease state and indication
Tapinarof initial indication is for psoriasis, AD is later and data no where near as convincing as rux cream
Roflumilast is a pde-4 like eucrisa and first indication will be psoriasis and again, data is not as strong for AD compared to rux cream
Oral JAKs are for moderate to severe AD and will carry a black box so will have bigger hurdles to overcome imo
Rux Cream is the only topical JAK that will hot market in next 1-2 years so great opportunity for 1st move like dupilumab.
Biologics for AD won’t be direct competitors for rux cream
Based on you citing agents that aren’t even indicated for AD, my gut tells me you don’t work here but are just looking to stir shit up on this thread.
The biggest hurdle for rux cream will be access, but without any other topical JAKs on market for at least 1-2 years, this will be Incyte’s blunder if it’s not a blockbuster. so please, continue to go on.

I think you two are referring to different things: one is talking AD competition and the other Derm job opportunities.

 

[anonymous]

I think you two are referring to different things: one is talking AD competition and the other Derm job opportunities.

Exactly. TLDR: someone wasted a Saturday night googling every Derm drug and there will be plenty of Dermatology/Immunology opportunities.

 

[anonymous]

Exactly. TLDR: someone wasted a Saturday night googling every Derm drug and there will be plenty of Dermatology/Immunology opportunities.

or someone who just knows their shit. After all, this is our chosen profession. If you truly work here, you literally just got here and you’re already bitching!? About what??…we don’t even have a product or label yet. Nor does any other product you rattled. All in the FDA’s hands. And you’re already on to the next opp!? Just leave now loser, no one wants your kind here.

 

[anonymous]

or someone who just knows their shit. After all, this is our chosen profession. If you truly work here, you literally just got here and you’re already bitching!? About what??…we don’t even have a product or label yet. Nor does any other product you rattled. All in the FDA’s hands. And you’re already on to the next opp!? Just leave now loser, no one wants your kind here.

Wake up! That’s pharma! Sometimes gigs are a bust and you need to move on and cut your losses. Don’t act like your resume is flawless with 10 years at each company.

 

[anonymous]

Wake up! That’s pharma! Sometimes gigs are a bust and you need to move on and cut your losses. Don’t act like your resume is flawless with 10 years at each company.

I disagree, that’s just YOUR entitled, impulsive, and “grass-is-always greener” personality.

 

[anonymous]

I disagree, that’s just YOUR entitled, impulsive, and “grass-is-always greener” personality.

Ummm, no. It’s called “I need to pay bills and feed my children” attitude. PS your privilege is showing

 

[anonymous]

Ummm, no. It’s called “I need to pay bills and feed my children” attitude. PS your privilege is showing

maybe don’t overextend yourself with all those luxury handbags you buy.

 

[anonymous]

maybe don’t overextend yourself with all those luxury handbags you buy.

I don’t, they make great fakes these days.

 

[anonymous]

I don’t, they make great fakes these days.

touche’ I hope you get yours then!

 

[anonymous]

bimi is for psoriasis, different disease state; tapinarof is going for initial psoriasis indication, AD is later and data is no where near as convincing as rux; oral JAKs are for moderate to severe and will carry a black box; roflumilast is a PDE-4 like eucrisa which again doesn’t have as strong of data and whose first indication will be for psoriasis. Yes there will be competitors but rux cream has a clear advantage of being first to market by a long shot for any other topical competing for the AD indication. Biologics will NOT be direct competitors to rux cream imo. My hunch is you don’t work here, but are just stirring shit up on this board, otherwise you wouldn’t be citing psoriasis products as competitors.

Agree with this. That person is stirring the pot. Morale is high on my team. No one sees this delay are hurting us and rux data is strong. There will always be competition in every market. If there wasn’t they wouldn’t need reps. I’m confident in our product.

 

[anonymous]

Ummm, no. It’s called “I need to pay bills and feed my children” attitude. PS your privilege is showing

Um, we are still getting paid full base and bonus. If you can’t live off of your base and bonus payout, then something is being done wrong on your part. When the product launches of course we will make more, but consider yourself fortunate they decided to give us full bonus payout despite the delay. Starting to think maybe you don’t actually work here because it doesn’t seem like you know we are still getting paid out.